Michael Luzzio

USPTO Granted Patents = 50 (Patent Applications = 38)

CIPO Patents = 5 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 16)

Average Co-Inventor Count = 3.6

ph-index = 14

Forward Citations = 546(Granted Patents)

Forward Citations (Not Self Cited) = 494(Oct 12, 2025)

Location History:

Durham, NC (US) (1992 - 2002)
Groton, CT (US) (2002 - 2021)
Waltham, MA (US) (2022)
Noank, CT (US) (2006 - 2024)

Company Filing History:

Skyhawk Therapeutics, Inc.

Smithkline Beecham Corporation

Agouron Pharmaceuticals, Inc.

Astex Therapeutics Limited

Edgewise Therapeutics, Inc.

patents

13. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1992-2025

Loading Chart...

50 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12448369 - Quinolinone amide compounds and uses thereof (2025-10-21),

2. 11964971 - Methods and compositions for modulating splicing (2024-04-23),

3. 11845744 - Methods and compositions for modulating splicing (2023-12-19),

4. 11603531 - Methods and compositions for modulating splicing (2023-03-14),

5. 11530207 - Compounds for the treatment of cancer (2022-12-20),

6. 11505541 - Protein kinase C inhibitors and methods of their use (2022-11-22),

7. 11434489 - Methods and compositions for modulating splicing (2022-09-06),

8. 11326165 - Methods and compositions for modulating splicing (2022-05-10),

9. 11168095 - ASK1 inhibiting agents (2021-11-09),

10. 11162101 - Methods and compositions for modulating splicing (2021-11-02),

11. 11129829 - Methods for modulating splicing (2021-09-28),

12. 11091475 - Methods and compositions for modulating splicing (2021-08-17),

13. 11059804 - Protein kinase C inhibitors and methods of their use (2021-07-13),

14. 11021708 - Methods and compositions for modulating splicing (2021-06-01),

15. 11008572 - Methods and compositions for modulating splicing (2021-05-18),

Title: Michael Luzzio: Innovator in mRNA Modulation

Introduction: Michael Luzzio, based in Noank, CT, has made significant contributions to the field of molecular biology, particularly in the realm of mRNA modulation. With an impressive portfolio of 32 patents, he is recognized for his work on small molecule splicing modulators that have potential implications for treating various diseases.

Latest Patents: Among his notable inventions, two recent patents stand out: "Methods and compositions for modulating splicing." These patents describe innovative small molecule splicing modulator compounds designed to regulate mRNA splicing, specifically targeting pre-mRNA encoded by genes. The patents further detail pharmaceutical compositions that comprise these compounds and outline methods for their application in modulating splicing, with the goal of treating a variety of diseases and conditions.

Career Highlights: Michael has worked with prominent companies in the pharmaceutical and biotech sectors. He has been affiliated with Pfizer Corporation and Skyhawk Therapeutics, Inc., where he harnessed his expertise to drive forward innovative research and development in therapeutic solutions.

Collaborations: Throughout his career, Michael has collaborated with other esteemed professionals in the field, including John Charles Kath and Kathleen McCarthy. These partnerships have enriched his work and have contributed to advancements in molecular modulation technologies.

Conclusion: With a robust collection of patents and a career marked by significant collaborations, Michael Luzzio stands at the forefront of innovation in mRNA technology. His work has the potential to pave the way for new treatments, making a substantial impact on the healthcare landscape.

This text is generated by artificial intelligence and may not be accurate.